JAVMA news
Beware of prescribing pitfalls
A veterinarian who dispenses a drug without a client-patient relationship may be acting outside the scope of veterinary medicine.
JAVMA news
AAVSB offers regulatory guidance during opioid crisis
The Model Regulations for Appropriate Use of Opioids in Veterinary Medicine were developed by the AAVSB Regulatory Policy Task Force in response to…
Compounding guidance for veterinarians
Learn about the regulatory parameters, quality control assurance, and practice considerations when using compounded products in veterinary medicine.
blog
Report identifies antimicrobial-resistant pathogens impacting animal health
A new report on antimicrobial-resistant pathogens and their impact on animal health is now available for AVMA members to download.
JAVMA news
Studies aim to improve antimicrobial prescribing in pets
A national survey could help quantify how often and why antimicrobials are administered in U.S. companion animal clinics.
JAVMA news
HOD passes resolution on workforce issues
AVMA leaders resolved to help address economic, staffing, and morale challenges in the veterinary workforce and they adjusted a series of existing…
JAVMA news
DEA, pharmacy come to terms on compounding
A recent agreement between a compounding pharmacy and the federal agency responsible for drug enforcement activities provides greater clarity for how…
JAVMA news
Chicago responds to canine influenza
Both dogs were among the victims of an outbreak of canine influenza ongoing as of late April in the Chicago area.
JAVMA news
DEA revokes pharmacy's registration
Veterinarians were reminded of the regulations for obtaining compounded controlled substances when the Drug Enforcement Administration
AVMA news
AVMA members press Congress for illicit xylazine, dog importation laws
Nearly 120 veterinarians and veterinary students attended the 2023 AVMA annual legislative fly-in, held April 17-19 in Washington, D.C. They urged…
Compounding from bulk drug substances
Learn about GFI #256, which clarifies the circumstances under which FDA does not intend to pursue enforcement action for compounding animal drugs from…